Provenance Record

[{"url":"https://www.statnews.com/2026/03/18/azalea-therapeutics-signs-of-success-in-vivo-car-t-therapy/","status":"verified","findings":"Confirms Nature publication on March 18, 2026. Confirms Justin Eyquem as senior author at UCSF. Confirms quote about 'reliably genetically edit the right cells and the right part of those cell's genomes.' Confirms Doudna as co-founder. STAT article is paywalled but summary confirms key claims. The $82M financing detail attributed to STAT could not be verified from the accessible portion."},{"url":"https://www.globenewswire.com/news-release/2026/03/18/3258448/0/en/Azalea-Therapeutics-Highlights-Nature-Publication-Demonstrating-In-Vivo-Site-Specific-TRAC-CAR-T-Cell-Engineering.html","status":"verified","findings":"Confirms ~20% splenic T cells achieved via single administration. Confirms complete B cell aplasia and tumor clearance. Confirms TRAC locus insertion and endogenous promoter control. Confirms co-founders: Eyquem, Hamilton, Doudna. Confirms UCSF and UC Berkeley collaboration. Press release does NOT mention $82M financing figure."},{"url":"https://www.nature.com/subjects/gene-therapy","status":"inaccessible","findings":"This is a Nature subject landing page, not the actual research paper. It returned HTTP 303. The article references a Nature publication but the actual paper URL is not provided as a source. The study's existence is confirmed by both STAT and GlobeNewsWire."}]

Key scientific claims verified: two-vector system (EDV + AAV), TRAC locus integration, ~20% splenic T cells, complete B cell aplasia, tumor clearance without lymphodepletion. Founding team (Eyquem, Hamilton, Doudna) confirmed. The $82M financing claim is attributed to STAT but could not be verified from the accessible portion of the paywalled article. The third source is a Nature subject page, not the actual paper — this is a weak source but the study's existence is independently confirmed.

Strong biotech news article with solid sourcing from STAT and Azalea's own press release. Scientific claims are well-supported and properly attributed. The competitive landscape section adds valuable context. Minor concerns about the Nature subject page source and unverifiable financing figure do not undermine the article's core claims.